Much of the discussion around compliance in pharmaceutical marketing continues to focus on the latter stages of a campaign – creative approval, MLR review cycles, and regulatory sign-off. Yet a significant proportion of regulatory complexity is determined well before any of this, at the media planning stage.
In highly regulated markets, where frameworks such as the ABPI Code of Practice for the Pharmaceutical Industry 2024, published by the Association of the British Pharmaceutical Industry, establish rigorous standards for the promotion of medicines, the choice of channels, formats, and placement environments has a direct bearing on the level of regulatory risk a campaign will face throughout its execution.
The starting point
The ABPI Code of Practice 2024, administered by the Prescription Medicines Code of Practice Authority, defines promotion broadly, encompassing any activity that encourages the prescribing, supply, or use of medicines. This definition applies regardless of format, including digital media, printed materials, events, and direct interactions.
The Human Medicines Regulations 2012, overseen by the Medicines and Healthcare products Regulatory Agency, further reinforce that any communication with promotional intent is subject to regulatory oversight.
In practice, this means that channel selection determines the nature of audience exposure, the degree of control over who receives the message, and the likelihood of that message reaching inappropriate audiences. The very same piece of content may be entirely appropriate within an environment restricted to healthcare professionals, yet problematic when distributed through an open channel.
Not all environments carry the same risk
Media environments differ considerably in terms of regulatory risk. Open platforms, particularly digital and social channels, tend to maximise reach, but at the cost of distribution predictability.
In accordance with guidance from the Medicines and Healthcare products Regulatory Agency set out in the Blue Guide: Advertising and Promotion of Medicines in the UK (2020), content directed at healthcare professionals should ideally be placed within environments featuring controlled access or clearly defined audience segmentation.
This approach reduces the likelihood of prescription medicines being exposed to the general public, of scientific content being misinterpreted, and of indirect breaches of promotional rules. Specialist editorial environments, by contrast, offer considerably greater predictability, operating with qualified audiences and a well-defined clinical context.
Open platforms versus curated environments
Open platforms are built on scale and automation, which inherently limits control over where and to whom a message is delivered. Specialist editorial environments, on the other hand, operate with more precise segmentation and content governance, characteristics that facilitate alignment with regulatory requirements.
This distinction becomes particularly significant in light of the ABPI Code 2024’s requirement that promotion be directed appropriately and that communication with ineligible audiences be avoided. The risk, therefore, does not reside solely in the message itself, but in the context in which it appears.
Independent media planning
Independent media planners tend to evaluate channels through a broader lens — one that encompasses regulatory risk, audience quality, and contextual appropriateness alongside conventional performance metrics.
This approach makes it possible to avoid channels that, whilst efficient in terms of cost or reach, introduce additional complexity into the compliance process. Without reliance on proprietary inventory or specific commercial agreements, planning can prioritise safer, more appropriate environments from the outset, reducing the need for subsequent adjustments, lowering the risk of non-compliance, and contributing to a more seamless campaign execution.
Brand safety
In regulated categories, audience quality ceases to be merely a performance variable, it becomes a compliance requirement.
British regulation stipulates that communications must be appropriate for the intended audience, and that prescription medicines must not be promoted to the general public. This establishes a direct relationship between who receives the message, where it appears, and whether it meets regulatory standards.
Environments with low audience predictability simultaneously elevate both regulatory and reputational risk. Conversely, channels with verified audiences and appropriate contextual alignment tend to offer not only greater regulatory security, but also more meaningful and relevant communication.
Performance as a by-product of compliance
Contrary to a common assumption, aligning media strategy with regulatory requirements does not constrain performance – it tends to enhance it. Reducing regulatory risk means reducing wasted investment. This occurs because communication reaches more qualified audiences; the context supports the correct interpretation of the message; there are fewer disruptions caused by revisions or rejections; and the overall engagement journey becomes more consistent and coherent.
Questions to ask before planning begins
Before embarking on a campaign, it is essential to understand how your agency approaches the regulatory dimension within its media planning process. The following questions can bring valuable clarity:
- How are channels assessed in terms of regulatory risk?
- What mechanisms are in place to ensure that the audience comprises healthcare professionals?
- How is exposure managed across open digital environments?
- And is there meaningful integration between media planning and compliance functions?
The difference a specialist approach makes
Agencies with deep healthcare expertise tend to embed regulatory knowledge directly into the planning process. This means that decisions around channels, formats, and environments are made from the outset with frameworks such as the ABPI Code of Practice 2024 in view, resulting in more considered choices, reduced need for rework, and greater predictability in campaign execution.
Generalist approaches, by contrast, frequently treat compliance as a consideration that arises only after the strategy has been defined – significantly increasing operational complexity downstream.
It bears emphasising that in the pharmaceutical context, compliance does not begin at the point of content approval. It begins with the decision about where that content will be distributed. Frameworks such as the ABPI Code of Practice 2024 and the oversight of the Medicines and Healthcare products Regulatory Agency make clear that all promotional communications are subject to rigorous rules, irrespective of format or channel.
By treating channel selection as a strategic risk decision – rather than simply a question of reach – pharmaceutical brands can reduce friction, improve efficiency, and operate with greater confidence in a regulated environment.
